ASSOCIATION OF DELETION 13Q14 WITH CLINICOPATHOLOGIC FEATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA
Objective: To determine the frequency of Del 13q14 in Chronic lymphocytic leukaemia, to compare its association with clinicpathologic features and to define the contribution of this abnormality to the prognosis. Study Design: Cross-sectional study. Place and Duration of Study: Department of Ha...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Army Medical College Rawalpindi
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0ea462e6b62c4120ab8c952dc6099058 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Objective: To determine the frequency of Del 13q14 in Chronic lymphocytic leukaemia, to compare its association with clinicpathologic features and to define the contribution of this abnormality to the prognosis.
Study Design: Cross-sectional study.
Place and Duration of Study: Department of Haematology, Armed Forces Institute of Pathology, Armed Forces Bone Marrow Transplant Centre and Oncology department, Combined Military Hospital Rawalpindi, from Apr 2017 to Jul 2018.
Methodology: A total of 56 newly diagnosed cases of CLL were included in the study. Patients were diagnosed on the basis of National Cancer Institute Working Group guidelines for diagnosis of CLL. After detailed history and thorough clinical examination; complete blood counts, biochemical profile, bone marrow examination, immunophenotyping on bone marrow or peripheral blood samples were done and Interphase FISH studies on blood or bone marrow specimens for detection of Del 13q14 were performed. Clinico-pathological features of CLL patients with Del 13q14 were compared with other cytogenetic abnormalities.
Results: The frequency of Trisomy 12 was found to be 37.5%. Most of CLL patients with Del 13q14 were aymptomatic and were diagnosed on routine workup. The WBC count and Absolute lymphocyte count was slightly lower in patients with Del13 q14 lower when compared with the CLL patients without 13q14 Deletion. Most of the patients with this aberration presented in early stage (Binet stage A) and this association of Del 13q14 with Binet stage was statistically significant (p<0.05). However, no association was found between 13q14 deletion and ZAP70 as all of our patients were negative for this marker. Many patients with Del 13q14 did not require chemotherapy at diagnosis and during follow up as compared to patients without del13q14, and this association was statistically significant (p<0.05). The study also showed that disease progression in patients with deletion 13q14 become significantly less as compared to patient without Del 13q14.
Conclusions: The deletion of 13q14 influence clinical outcome of patients with CLL and was found to be associated with favourable prognosis. A determination of Del 13q14 should therefore be included in the investigations of the prognostic factors of B-cell chronic lymphocytic leukemia. This can prevent unwanted chemotherapy in these patients. |
|---|